Member Posts > Cardiol Therapeutics: New Research Highlights Cannabidiol's Potential in Heart Failure Therapy
Cardiol Therapeutics Inc., a leader in cardiovascular drug development, has published new findings in JACC: Basic to Translational Science on how cannabidiol (CBD) may counteract heart failure progression. The study, "Cannabidiol Prevents Heart Failure Dysfunction and Remodeling Through Preservation of Mitochondrial Function and Calcium Handling," details CBD's mechanisms in reducing cardiac fibrosis, inflammation, and mitochondrial dysfunction-key drivers of heart failure with preserved ejection fraction (HFpEF).
Study Insights
• CBD reduced fibrosis, inflammation, and hypertrophy in an in vivo heart failure model.
• Enhanced mitochondrial function and calcium regulation contributed to improved cardiac performance.
• CRD-38 may offer a novel therapeutic approach by targeting cellular pathways linked to heart failure.
Dr. Andrew Hamer, Chief Medical Officer at Cardiol, noted that these findings validate CBD's cardioprotective effects, reinforcing the company's commitment to bringing CRD-38 into clinical trials.

#CardiolTherapeutics #InvestorRelations #StockMarket #HealthcareInvestments #BiotechStocks #Pharmaceuticals #CardiacCare #FinancialUpdates #HeartHealth #MedicalInnovation #Pericarditis #HealthcareResearch #AdvancedTherapies #CardiolRx #CRD38 #Myocarditis